Get the Stockscreener App
5.07
3.24%
-0.17
After Hours:
5.06
-0.01
-0.20%
Vir Biotechnology Inc stock is traded at $5.07, with a volume of 932.33K.
It is down -3.24% in the last 24 hours and up +0.60% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$5.24
Open:
$5.23
24h Volume:
932.33K
Relative Volume:
0.73
Market Cap:
$700.87M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.2934
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
-11.98%
1M Performance:
+0.60%
6M Performance:
-51.25%
1Y Performance:
-50.10%
1-Day Range:
$5.04
$5.27
1-Week Range:
$5.04
$5.765
52-Week Range:
$4.32
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.07 | 724.37M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
How many analysts rate Vir Biotechnology Inc. as a “Buy”Post Market Picks With Low Risk - jammulinksnews.com
Vir Biotech enrolls first patient in hepatitis delta virus trial - Investing.com Australia
Vir Biotechnology enrolls first patient in ECLIPSE 2 hepatitis delta trial - StreetInsider
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
How strong is Vir Biotechnology Inc. company’s balance sheetEarnings Report Guidance For Smart Trading - jammulinksnews.com
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Custom Dashboard Highlights Vir Biotechnology Inc. Price MomentumWeekly Setup With 3x Return Potential Published - metal.it
Is Vir Biotechnology Inc. a Top Dividend Stock to Watch in 2025Chart-Based Trade Entries Gain Analyst Support - metal.it
Vir Biotechnology Begins Phase 1 Trial for VIR-5525 - MSN
Why Vir Biotechnology Inc. stock attracts strong analyst attentionInvestment Playbook for Growing Markets Shared - metal.it
Vir Biotechnology Inc. Attempts Reversal From Key SupportSector Based Breakout Stock Forecast Issued - metal.it
Vir Biotechnology Inc. Stock Fails to Break Resistance Traders ReactEntry and Exit Strategy Optimizer Tool Tested - metal.it
Why is Vir Biotechnology Inc. stock attracting strong analyst attentionOutstanding trading profits - jammulinksnews.com
Is Vir Biotechnology Inc. a growth stock or a value stockDiscover market opportunities with real-time data - jammulinksnews.com
Sectors Driving Future Growth for Vir Biotechnology Inc. Stock5x Profit Potential - metal.it
Should I hold or sell Vir Biotechnology Inc. stock in 2025Market-beating returns - jammulinksnews.com
How volatile is Vir Biotechnology Inc. stock compared to the marketFree Stock Market Beginners Guide - jammulinksnews.com
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? - MSN
Does Vir Biotechnology Inc. stock pay reliable dividendsFree Trading Psychology Coaching - jammulinksnews.com
Is Vir Biotechnology Inc. a good long term investmentExplosive wealth accumulation - PrintWeekIndia
First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525 - Yahoo Finance
Don't Ignore The Insider Selling In Vir Biotechnology - 富途牛牛
Vir Biotechnology doses first patient in VIR-5525 trial - TipRanks
Vir Biotechnology doses first patient in EGFR-targeted cancer trial By Investing.com - Investing.com South Africa
Vir Biotechnology doses first patient in EGFR-targeted cancer trial - Investing.com
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors - Business Wire
Vir Biotechnology Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional
What drives Vir Biotechnology Inc. stock priceUnstoppable investment returns - Autocar Professional
Vir Biotechnology: Hep D And Cancer Projects March On (NASDAQ:VIR) - Seeking Alpha
Have Insiders Sold Vir Biotechnology Shares Recently? - simplywall.st
What analysts say about Vir Biotechnology Inc. stockRapidly expanding wealth - jammulinksnews.com
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire
(VIR) Investment Analysis and Advice - news.stocktradersdaily.com
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):